Dr. John Eisenbrey’s lab at Thomas Jefferson University focuses on improving imaging techniques for detecting recurrent cancers, particularly using contrast-enhanced ultrasound (CEUS). They aim to refine methods for assessing responses to treatments like renal cancer ablation and liver cancer chemoembolization. The lab's goal is to enhance the accuracy of these imaging technologies, making cancer detection and treatment assessment faster and more effective for patients.

Dr. Ruijiang Li's lab focuses on developing advanced imaging techniques and blood-based biomarkers to personalize cancer treatments, particularly for lung, oropharyngeal, gastric, and rectal cancers. The research aims to enhance prediction of patient responses to immunotherapy and other treatments, which could ultimately improve outcomes and help tailor therapies to individual patients' needs.

Dr. Kai Chen's lab at USC focuses on improving cancer imaging techniques, specifically through the development of a new PET imaging tracer called [18F]FMAU that measures cancer cell proliferation. The lab is leveraging innovative droplet radiochemistry technology to enhance the production of this tracer, making it faster, safer, and more widely accessible for clinical use. This research aims to provide better tools for assessing tumor responses to treatments, ultimately improving patient care and therapeutic outcomes.

Dr. James Peter Basilion's research lab focuses on improving cancer treatment through innovative imaging and therapeutic techniques. By developing specialized agents that target cancer cells, they aim to enhance surgical precision while boosting the immune response to prevent recurrence and metastasis. Their work combines fluorescence-guided surgery with photodynamic and photothermal therapies to address unmet clinical needs in prostate and breast cancer treatments.

Cristian T Badea's lab at Duke University focuses on advancing cancer treatment and non-invasive imaging techniques. They develop innovative platforms to improve the understanding of complex tumors, particularly in head and neck cancers, while also enhancing the detection of aneurysms in the brain using advanced imaging technologies. Their research aims to combine imaging innovations with therapy optimization to enable personalized medicine.

Dr. Bernadette Marquez-Nostra's lab focuses on improving cancer treatment response for patients with aggressive forms of breast and lung cancer. By developing advanced imaging techniques, the lab aims to better understand how new bispecific antibodies work to target cancer cells. This research hopes to make it easier for doctors to identify which patients will benefit most from these therapies, potentially transforming treatment approaches for cancer.

Dr. Luisa Escobar Hoyos's lab at Yale University focuses on uncovering new ways to enhance the immune response against cancers, particularly through T-cell activation. Research efforts aim to understand how RNA splicing defects influence T-cell function and how targeting these defects can improve cancer immunotherapy. The lab also studies the implications of specific mutations in pancreatic cancer, aiming to develop therapies that correct these mutations to better combat aggressive tumor growth.

Dr. Christopher J. Bakkenist's lab focuses on understanding how certain cancer treatments can inadvertently affect the immune system. Specifically, they study how deoxyuridine, a byproduct of chemotherapy, impacts the way the body's immune system recognizes and responds to DNA contamination. This research aims to uncover mechanisms that may enhance the effectiveness of cancer therapies and improve patient outcomes.

Dr. Fen Xia's lab focuses on improving cancer treatment, specifically for head and neck squamous cell carcinoma (HNSCC). They investigate how certain proteins affect the immune response to tumors, particularly how a pathway involving GSK3 and 53BP1 can lead to T cell exhaustion, which limits the success of immunotherapies. By understanding and disrupting this pathway, the lab aims to enhance T cell survival and effectiveness against tumors, contributing to better treatment options.

Dr. David J. Odde's laboratory focuses on engineering innovative solutions for improving cancer immunotherapy, particularly for challenging cancers like pancreatic ductal adenocarcinoma and glioblastoma. By developing a multiscale tumor simulator, this team predicts tumor dynamics and the interaction between cancer cells and immune cells, guiding the development of more effective immunotherapies. The lab combines expertise in biomedical engineering, immunology, and genetic engineering to create a robust platform for cancer research and treatment.

Dr. Daniel M Spielman's lab at Stanford University is focused on innovative cancer therapies and imaging techniques. Their aim is to improve the treatment and diagnosis of resistant cancers like glioblastoma by utilizing novel lipid-based drugs that target tumor energy metabolism. By developing advanced MRI techniques, the lab is working to better understand metabolic changes in tumors and enhance treatment response monitoring.

David Mankoff's lab focuses on understanding how certain aggressive cancers, particularly triple-negative breast cancer, utilize glutamine metabolism and glutamate transport to survive and resist treatment. They are developing advanced imaging techniques using positron emission tomography (PET) to measure these metabolic processes and to identify patients who may benefit from specific therapies targeting these pathways. By linking imaging data to treatment response, the lab aims to improve personalized cancer therapies and outcomes for patients.

Dr. Gregory Gan's lab focuses on understanding how a specific protein, MK2, affects the behavior of head and neck cancer cells, particularly their ability to migrate and invade other tissues. By exploring the role of MK2 in cancer metastasis, the lab aims to develop new strategies that could improve treatments and ultimately enhance survival rates for patients with head and neck squamous cell carcinoma. Their work includes using innovative techniques to study cancer cells and their interactions in a lab setting, which could lead to promising clinical applications.

Dr. Andrew Zhuang Wang's lab at UT Southwestern Medical Center focuses on creating advanced models to study how cancer spreads, particularly to specific organs. By engineering tissues that mimic these organs, they aim to understand the factors that influence metastasis and improve cancer treatment strategies. The lab's innovative approach combines biology and engineering to develop tools that could lead to breakthroughs in precision medicine for cancer patients.

Dr. France Carrier's lab at the University of Maryland Baltimore focuses on developing innovative cancer therapies that combine small molecules to target key cellular pathways involved in cancer progression and immune evasion. The research aims to create less toxic treatments that can more effectively combat drug resistance in various cancers. The team employs a mix of medicinal chemistry, structural biology, and cancer biology to create and test these new therapeutic agents.

Dr. Steven Hetts' lab is focused on developing innovative devices to improve cancer treatment by minimizing the systemic side effects of chemotherapy. They create specialized filters that can remove chemotherapy drugs from the bloodstream after they have targeted tumors, helping to reduce overall toxicity. The lab works on modeling, testing, and optimizing these devices to make cancer treatments more effective and safer for patients.

Dr. Michael Markl's lab at Northwestern University focuses on advancing cardiac imaging techniques to improve patient outcomes in heart diseases. They are developing state-of-the-art MRI technology, particularly four-dimensional (4D) flow MRI and cardiac MRI, to assess blood flow and tissue health in individuals with congenital heart defects and heart transplant patients. The lab uses artificial intelligence to streamline imaging processes and enhance analysis accuracy, ultimately aiming to establish non-invasive methods for better predicting and managing heart complications.

Dr. Megan Laura Mccain's lab at USC focuses on understanding heart injuries, particularly how oxygen levels affect the communication between different cell types in the heart after a heart attack. They use advanced technologies to create models that mimic heart conditions, enabling them to study how these interactions can lead to better treatments for patients recovering from heart attacks. Through their work, they hope to develop new therapies to improve heart health and outcomes.

Dr. Reza Avazmohammadi's lab focuses on understanding heart function, especially how the heart's ventricles relax and adapt under different conditions. They explore the mechanics behind heart diseases like heart failure and pulmonary hypertension by using advanced imaging and deep learning techniques. The goal is to identify ways to treat these conditions more effectively by examining both passive and active changes in heart tissue.

Dr. Peder Eric Zufall Larson’s lab focuses on using advanced magnetic resonance imaging (MRI) techniques to understand heart disease, particularly how changes in heart metabolism can influence various heart conditions. By developing a specialized method called hyperpolarized 13C MRI, the lab aims to investigate metabolic remodeling in patients with hypertrophic cardiomyopathy, a common inherited heart condition. Their work has implications for better diagnosis and management of heart diseases through improved imaging processes.